AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
Speaking during a company event, Dale said he was drawn to AxoGen because peripheral nerve function represents a “credible health condition” with a large underserved patient population and because the company’s Avance platform offers what he described as a differentiated solution relative to existing standards of care.
